| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| TAX PREPARATION | 4,950 | 0 | 4,950 | 0 |
| Identifier | Return Reference | Explanation |
|---|---|---|
| CONTINUATION OF SUMMARY OF DIRECT CHARITABLE ACTIVITIES DESCRIPTION | FORM 990-PF, PART VIII-A SUMMARY OF DIRECT CHARITABLE ACTIVITIES | THE A. F. ROTHSCHILD FUND IS AN INDEPENDENT PRIVATE OPERATING FOUNDATION DEDICATED TO THE WELL-BEING AND PROTECTION OF HORSES, DONKEYS, AND RELATED MEMBERS OF THE GENUS EQUUS THROUGH DIRECT ENGAGEMENT IN SCIENTIFIC RESEARCH, ACADEMIC SCHOLARSHIP, LEGAL INTERVENTION, AND EDUCATIONAL PROJECTS AS PROGRAM INITIATIVES OF THE CENTER FOR CONTEMPORARY EQUINE STUDIES (CCES), A SUPPORTING ORGANIZATION HEADQUARTERED IN WOODSIDE,CA.PRINCIPAL DIRECT ACTIVITIES DURING 2024 INCLUDED:I. LEGAL ACTIONA CONTINUING LAWSUIT FILED WITH THE CA SUPERIOR COURT IN 2022 TO PROHIBIT THE SALE OF "EJIAO" PRODUCTS, A PURPORTEDLY ANCIENT TRADITIONAL CHINESE MEDICINE MANUFACTURED FROM THE HIDES OF SLAUGHTERED DONKEYS AND UNLAWFULLY MARKETED IN VARIOUS FORMS AS AN HERBAL FOOD SUPPLEMENT/NUTRACEUTICAL IN VIOLATION OF CA STATUTORY LAW BANNING SALES OF EQUINE MEAT PRODUCTS FOR HUMAN CONSUMPTION. THE FUND'S PRECENDENTIAL LAWSUIT, FILED IN 2022, MARKS THE FIRST JUDICIAL CASE SINCE THE PROHIBITION WAS ENACTED 30 YEARS AGO AND IS PRESENTLY SCHEDULED FOR SUMMARY JUDGMENT ON SEPT. 15, 2025.II. RESEARCH AND EDUCATION:1) SUCCESSFUL COMPLETION OF A 5-YEAR RESEARCH PROJECT TO DEVELOP A NOVEL BIOTECHNOLOGICAL ALTERNATIVE TO REPLACE THE SCIENTIFICALLY OBSOLUTE & ETHICALLY UNACCEPTABLE USE OF HORSES AS LIVING INCUBATORS FOR INDUSTRIAL MASS PRODUCTION OF ANTIBODY-BASED ANTIVENOMS. THE GROUNDBREAKING PILOT STUDY, JOINTLY FUNDED BY THE PETA INT'L SCIENCE CONSORTIUM, DEMONSTRATED THAT ANTIBODIES PRODUCED USING RECOMBINANT METHODS ARE HIGHLY EFFECTIVE IN NEUTRALIZING BLACK WIDOW VENOM. THE INNOVATIVE METHODOLOGY AND TEST RESULTS WERE PUBLISHED IN THE JUNE 2024 ISSUE OF THE LEADING SCIENTIFIC JOURNAL FRONTIERS IN IMMUNOLOGY.2) COMPREHENSIVE LEGAL REVIEW OF THE BRAZIL FEDERAL GOVERNMENT'S REGULATORY REQUIREMENTS FOR APPROVAL OF EQUINE-DERIVED PHARMACEUTICAL PRODUCTS AND COMPLIANCE BY DRUG MANUFACTURERS WITH ANIMAL WELFARE LAWS PERTAINING TO USE OF HORSES AS LIVING MEANS OF PRODUCTION.3) A CONTINUING INVESTIGATIVE INQUIRY CONCERNING THE HEALTH AND WELFARE OF HORSES USED FOR ANTIBODY PRODUCTION BY THE PHARMACEUTICAL INDUSTRY AS EVIDENCED BY THE VISIBLE AND INTERNAL PATHOLOGICAL EFFECTS OF THE ROUTINE PROCEDURAL PROTOCOLS, AND WHICH TO DATE HAVE BEEN WITHHELD FROM PUBLIC KNOWLEDGE.4) DEVELOPMENT AND SUBMISSION OF A FORMAL WHITE PAPER CONTESTING THE EXCLUSION OF HORSES FROM THE BRAZILIAN NATIONAL COUNCIL ON ANIMAL EXPERIMENTION'S LEGISLATIVE REFORMS FOR REGULATION OF "THE REUSE, SEQUENTIAL USE AND RELOCATION OF ANIMALS IN SCIENTIFIC RESEARCH."III. PEER REVIEW PUBLICATIONS AND CONFERENCE PRESENTATIONS (ABRIDGED:RUSCHIG, M., NERLICH, J., HUST, M., ET. AL (2024) "HUMAN ANTIBODIES NEUTRALIZING THE ALPHA-LATROTOXIN OF THE EUROPEAN BLACK WIDOW," FRONTIERS IN IMMUNOLOGY, 15.PUCCA, MB & CAMPHORA, AL (2024) "THE POTENTIAL RISKS OF EQUINE SERUM THERAPY IN TRANSMITTING NEW INFECTIOUS DISEASES: LESSONS FROM A POST-PANDEMIC ERA." FRONTIERS IN PUBLIC HEALTH, 12.CAMPHORA, AL (2024)"HORSES AS A LIVING ASSET IN ANTIVENOM PRODUCTION: WHAT IS THEIR PHYSIOLOGICAL LIMIT?" INTERNATIONAL ANIMAL HEALTH JOURNAL, 11(3).CAMPHORA, A. L. (2024). THE ABUSIVE USE OF PREGNANT MARES IN THE PMSG INDUSTRY. INTERNATIONAL ANIMAL HEALTH JOURNAL, 11(1).CAMPHORA, A.L. (2024) "AT THE COST OF GIVING UP ALL THEIR BLOOD: HORSES AS GRIST FOR THE PHARMACEUTICAL INDUSTRY". IN: MARTINS, C. P. (ED) DO CAVALO: ON HORSES DEL CABALLO. EDITORA DIALTICA: 90-106."THE HORSE AS A MATERIAL ASSET IN MODERN IMMUNOLOGY," ANNUAL EQUINE HISTORY CONFERENCE, SEPT. 19-21, 2024."O ORGANISMO EQUINO A SERVIO DA PRODUO DE ANTIVENENOS: LACUNAS TICAS E RISCOS ASSOCIADOS," 2ND INTERNATIONAL SEMINAR ON BIOETHICS & ETHICS APPLIED IN THE FIELD OF ANIMAL LAW, AUG. 1, 2024. |
| Name of Bond | End of Year Book Value | End of Year Fair Market Value |
|---|---|---|
| APPLE INC AT 3.35% DUE 2/9/2027 | 25,534 | 25,902 |
| FORD MOTOR COMPANY DUE 8/1/2026 | 29,228 | 24,489 |
| Name of Stock | End of Year Book Value | End of Year Fair Market Value |
|---|---|---|
| 100 SHS CME GROUP INC | 10,167 | 23,223 |
| 105 SH ZOETIS INC. | 14,958 | 17,108 |
| 125 ALPHABET INC. | 15,346 | 23,663 |
| 130 SHS VISA INC | 10,198 | 41,085 |
| 160 SH VERIZON COMMUNICATIONS | 9,110 | 6,398 |
| 160 SHS MERCK & CO INC | 9,495 | 15,917 |
| 1350 SHS NVIDIA CORP | 5,377 | 181,292 |
| 260 SH COMCAST CORP | 10,053 | 9,758 |
| 330 SHS CISCO SYS INC | 9,884 | 19,536 |
| 360 SHS APPLE INC | 9,531 | 90,151 |
| 400 SHS SCHWAB US MID CAP ETF | 13,021 | 24,939 |
| 75 SHS TRAVELERS COMPANIES INC | 8,705 | 18,067 |
| 80 SH RESMED INC | 7,956 | 18,295 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| LEGAL FEES/ DUES | 97,644 | 0 | 0 | 97,644 |
| Description | Amount |
|---|---|
| FEDERAL EXCISE TAX | 210 |
| Description | Revenue and Expenses per Books | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| FUNDED RESEARCH | 9,030 | 0 | 0 | 9,030 |
| INTERNET AND IT | 38 | 0 | 38 | 0 |
| POSTAGE | 109 | 0 | 109 | 0 |
| OFFICE | 705 | 0 | 705 | 0 |
| DUES & SUBSCRIPTIONS | 93 | 0 | 93 | 0 |
| BAD DEBT EXPENSE | 250,000 | 0 | 250,000 | 0 |
| Description | Revenue And Expenses Per Books | Net Investment Income | Adjusted Net Income |
|---|---|---|---|
| LAWSUIT SETTLEMENT | 31,280 | 31,280 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| INVESTMENT MANGEMENT FEES | 3,420 | 3,420 | 3,420 | 0 |
| Category | Amount | Net Investment Income | Adjusted Net Income | Disbursements for Charitable Purposes |
|---|---|---|---|---|
| CALIFORNIA FILING FEES | 100 | 0 | 100 | 0 |